期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨转换的力学因素与骨质疏松(一)骨转换 被引量：1

Mechanical factors of bone change- over and osteoporosis
下载PDF
导出
摘要 骨组织的作用一是调节及分布无机质成分,协助维持血清钙浓度在一个很窄的范围,保持矿物盐在体内的平衡;二是进行骨重建,使骨对因负重和锻炼引起的力学改变作出反应,以维持骨骼的内在平衡.
作者 郭世绂
机构地区 天津医科大学总医院骨科
出处 《中国骨肿瘤骨病》 2002年第2期61-64,共4页 Chinse Journal Of Bone Tumor And Bone Disease
关键词 成骨细胞分化 骨形成 OC 骨转换 骨质疏松 骨吸收 脂肪细胞分化 RANKL 骨基质
分类号 R58 [医药卫生—内分泌]
  • 相关文献

参考文献28

  • 1[1]郭世绂,罗先正,邱贵兴.骨质疏松基础与临床.天津:天津科学技术出版社,2000.
  • 2[2]Martin TJ. Mechanisms by which cells of the osteoblast lineage control osteoblast formation and activity.J Cell Biochem, 1994,56:357- 366.
  • 3[3]Simonet WS,Lacey DI,Dunstan CR,et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89:309-319.
  • 4[4]Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc NatlA cad Sci USA, 1995,3597 -3602.
  • 5[5]Min H, Morony S, Sarosil, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med,2000, 192:463 - 474.
  • 6[6]Hofbauer LC, Khosla S. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. JBMR, 2000,15:2- 12.
  • 7[7]Suda T, Takahashi N, Udakawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev, 1999,2o:345- 357.
  • 8[8]Teitelbaum SL. Osteoclast biology. In Marcus R, Feldman D, Kelsey J eds Osteoporosis. Academic Press, San Diego, 1996,61 - 94.
  • 9[9]Radding W, Williams JP, Hardy RW, et al. Calmodulin concentrated at the osteoclast ruffled border modulates acid secretion. J Cell Physiol, 1994,160:17 - 28.
  • 10[10]Williams JP, McK enna MA, Thames AM, et al. Tamoxifen inhibits phorbol ester stimulated osteoclastic bone resorption: An effect mediated by calmodulin. Biochem Cell Biol,2000,78:715 - 723.

同被引文献21

  • 1郭世绂.骨转换的力学因素与骨质疏松(二)骨组织与力学环境[J].中国骨肿瘤骨病,2002,1(3):119-123. 被引量：3
  • 2[Khan SA, Kanis JA, Vasikamn S, et al. Elimination and biochemical responses to intravenous alendronate in Fostmenopau.sal osteoporosis[J ]. J Bone Miner Res, 1997, 12:1700-1707.
  • 3Black DM, Reiss TF, Nevitt MC, et al.Design of the fracture intervention trial[J]. Osteoporos Int, 1993, (Suppl 3):5129-39.
  • 4[Black DM, Ctmmfings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures[J]. Lancet, 1996, 348; 1535-1541.
  • 5Cummings SR, Karpf DB, Harris F, et al. Improvement in spinal bone density and reduction in risk of vertebral fractures during treatmen twith antiresorptive drugs[J]. Am J Med, 2002, 112: 281-289.
  • 6Bone HG, Adami S, Rizzoll R, et al. Weekly administration of alendronate: rationale and plan for clinical assessment[J]. Clin Therapeutics, 2000, 22:15-28.
  • 7Eastell R. Risedronate: a new blsphosphonate for the prevention and treatment of osteopomsls[J]. Clin Geriat, 2001, 9:1-9.
  • 8McClung MR, Geusens P, MiUar P, et al. Effect of risedronate on the risk of hip fracture in elderly women[J]. N Eng J Med, 2001, 344:333-340.
  • 9Harris ST, Watts NB, Genent HK, et al. Effects of risedronate treatment on vertebral end nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial [ J ]. JAMA,1999,282:1344-1352.
  • 10Ensrud DE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial[J]. Arch Intern Med, 1997, 157:2617-2624.

引证文献1

二级引证文献18

中国骨肿瘤骨病
2002年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部